Item 5.07 Submission of Matters to a Vote of Security Holders.
Cabaletta Bio, Inc., a Delaware corporation (the "Company") held its Annual
Meeting of Stockholders (the "Annual Meeting") on June 2, 2020. As of April 15,
2020, the record date for the Annual Meeting, there were 17,624,503 outstanding
shares of the Company's common stock. The Company's stockholders voted on the
following matters, which are described in detail in the Company's Definitive
Proxy Statement filed with the U.S. Securities and Exchange Commission on
April 23, 2020: (i) to elect one director, Brian Daniels, M.D., as a Class I
director of the Company to serve for a three-year term expiring at the Company's
2023 annual meeting of stockholders and until his successor has been duly
elected and qualified, subject to his earlier death, resignation or removal
("Proposal 1") and (ii) to ratify the appointment of Ernst & Young as the
Company's independent registered public accounting firm for the fiscal year
ending December 31, 2020 ("Proposal 2").
The Company's stockholders approved the Class I director nominee, Brian Daniels,
M.D., recommended for election in Proposal 1 at the Annual Meeting. The votes
cast at the Annual Meeting were as follows:
For Withheld Broker Non-Votes
9,666,638 1,147,329 823,061
The Company's stockholders ratified the appointment of Ernst & Young as the
Company's independent registered public accounting firm for the fiscal year
ending December 31, 2020, recommended for ratification in Proposal 2 at the
Annual Meeting. The votes cast at the Annual Meeting were as follows:
For Against Abstain Broker Non-Votes
11,529,472 107,556 0 0
No other matters were submitted to or voted on by the Company's stockholders at
the Annual Meeting.
Item 7.01 Regulation FD Disclosure.
On June 3, 2020, the Company posted to the "Investors & Media" section of the
Company's website at www.cabalettabio.com an updated corporate presentation
providing a corporate overview and updated development plan (the "Corporate
Presentation"). A copy of the Corporate Presentation is attached hereto as
Exhibit 99.1 and is incorporated by reference into this Item 7.01 of this
Current Report on Form 8-K.
The information contained in Item 7.01 of this Current Report on Form 8-K is
being furnished and shall not be deemed to be "filed" for the purposes of
Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange
Act"), or otherwise subject to the liabilities of that section and shall not be
incorporated by reference in any filing under the Securities Act of 1933, as
amended, or the Exchange Act, except as shall be expressly set forth by specific
reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
99.1 Cabaletta Bio, Inc. Corporate Presentation, dated June 3, 2020.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses